India Exchange Filings

Gland Pharma Q2 FY27 Earnings Summary

Gland Pharma Ltd reports Q2 FY27 revenue of ₹1,833.6 crore, up 23% year-on-year

  • Revenue rose 2% sequentially; PAT was ₹290.8 crore, up 58% year-on-year and down 8% sequentially.
  • Operating EBITDA margin was 26%, versus 27% in Q1 FY27 and 21% in Q2 FY26.
  • Adjusted EBITDA was ₹503 crore at a 27% margin, including a one-off GST-related provision adjustment.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.